Akebia Ther (AKBA) support and resistance · rev $102.7M
Akebia Ther (AKBA) is a drug manufacturers - specialty & generic company listed on US.
This page maps Akebia Ther (AKBA) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported AKBA revenue for 2026-06-30 was $102.7M. Net income was -$18.0M. Revenue was up 91.8% from 2026-03-31 to 2026-06-30. AKBA currently screens at market cap $260.1M.
AKBA currently screens at market cap $260.1M. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new AKBA 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the AKBA quote page for the session range and the stock page for the full model.
Not investment advice.